AAAAAA

   
Results: 1-25 | 26-50 | 51-51
Results: 1-25/51
Increased risk for ischaemic events is related to combined RAS polymorphism
Authors: van Geel, PP Pinto, YM Zwinderman, AH Henning, RH van Boven, A Jukema, JW Bruschke, AVG Kastelein, JJP van Gilst, WH
Citation: Pp. Van Geel et al., Increased risk for ischaemic events is related to combined RAS polymorphism, HEART, 85(4), 2001, pp. 458-462
Efficacy of concentrated n-3 fatty acids in hypertriglyceridaemia - A comparison with gemfibrozil
Authors: van Dam, M Stalenhoef, AFH Wittekoek, J Trip, MD Prins, MH Kastelein, JJP
Citation: M. Van Dam et al., Efficacy of concentrated n-3 fatty acids in hypertriglyceridaemia - A comparison with gemfibrozil, CLIN DRUG I, 21(3), 2001, pp. 175-181
Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study
Authors: Sijbrands, EJG Westendorp, RGJ Defesche, JC de Meier, PHEM Smelt, AHM Kastelein, JJP
Citation: Ejg. Sijbrands et al., Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study, BR MED J, 322(7293), 2001, pp. 1019-1022
Genetic and metabolic factors predicting risk of cardiovascular disease infamilial hypercholesterolemia
Authors: Smilde, TJ van Wissen, S Wollersheim, H Kastelein, JJP Stalenhoef, AFH
Citation: Tj. Smilde et al., Genetic and metabolic factors predicting risk of cardiovascular disease infamilial hypercholesterolemia, NETH J MED, 59(4), 2001, pp. 184-195
Genetic aspects of restenosis after percutaneous coronary interventions - Towards more tailored therapy
Authors: Agema, WRP Jukema, JW Pimstone, SN Kastelein, JJP
Citation: Wrp. Agema et al., Genetic aspects of restenosis after percutaneous coronary interventions - Towards more tailored therapy, EUR HEART J, 22(22), 2001, pp. 2058-2074
Molecular genetics and gene expression in atherosclerosis
Authors: Doevendans, PA Jukema, W Spiering, W Defesche, JC Kastelein, JJP
Citation: Pa. Doevendans et al., Molecular genetics and gene expression in atherosclerosis, INT J CARD, 80(2-3), 2001, pp. 161-172
A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: A randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease
Authors: van Dam, MJ Penn, HJAM den Hartog, FR Kragten, HA Trip, MD Buirma, RJA Kastelein, JJP
Citation: Mj. Van Dam et al., A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: A randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease, CLIN THER, 23(3), 2001, pp. 467-478
Results from a family and DNA based active identification programme for familial hypercholesterolaemia
Authors: ten Asbroek, AHA Marang-van de Mheen, PJ Defesche, JC Kastelein, JJP Gunning-Schepers, LJ
Citation: Aha. Ten Asbroek et al., Results from a family and DNA based active identification programme for familial hypercholesterolaemia, J EPIDEM C, 55(7), 2001, pp. 500-502
Measurement of atherosclerosis progression - Reply
Authors: Smilde, TJ van Wissen, S Kastelein, JJP Stalenhoef, AFH
Citation: Tj. Smilde et al., Measurement of atherosclerosis progression - Reply, LANCET, 358(9278), 2001, pp. 329-329
Familial hypercholesterolaemia - Reply
Authors: Umans-Eckenhausen, MAW Defesche, JC Sijbrands, EGJ Kastelein, JJP
Citation: Maw. Umans-eckenhausen et al., Familial hypercholesterolaemia - Reply, LANCET, 357(9269), 2001, pp. 1712-1712
Effect of aggressive versus conventional lipid lowering on atherosclerosisprogression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial
Authors: Smilde, TJ van Wissen, S Wollersheim, H Trip, MD Kastelein, JJP Stalenhoef, AFH
Citation: Tj. Smilde et al., Effect of aggressive versus conventional lipid lowering on atherosclerosisprogression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial, LANCET, 357(9256), 2001, pp. 577-581
Review of first 5 years of screening for familial hypercholesterolaemia inthe Netherlands
Authors: Umans-Eckenhausen, MAW Defesche, JC Sijbrands, EJG Scheerder, RLJM Kastelein, JJP
Citation: Maw. Umans-eckenhausen et al., Review of first 5 years of screening for familial hypercholesterolaemia inthe Netherlands, LANCET, 357(9251), 2001, pp. 165-168
Parental history of myocardial infarction: lipid traits, gene polymorphisms and lifestyle
Authors: Boer, JMA Feskens, EJM Kuivenhoven, JA Schouten, EG Havekes, LM Kastelein, JJP Seidell, JC Kromhout, D
Citation: Jma. Boer et al., Parental history of myocardial infarction: lipid traits, gene polymorphisms and lifestyle, ATHEROSCLER, 155(1), 2001, pp. 149-156
PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients
Authors: Leus, FR Zwart, M Kastelein, JJP Voorbij, HAM
Citation: Fr. Leus et al., PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients, ATHEROSCLER, 154(3), 2001, pp. 641-649
The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease
Authors: Clee, SM Loubser, O Collins, J Kastelein, JJP Hayden, MR
Citation: Sm. Clee et al., The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease, CLIN GENET, 60(4), 2001, pp. 293-300
Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolaemia - The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study
Authors: Smilde, TJ Trip, MD Wollersheim, H van Wissen, S Kastelein, JJP Stalenhoef, AFH
Citation: Tj. Smilde et al., Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolaemia - The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study, CLIN DRUG I, 20(2), 2000, pp. 67-79
Additional efficacy of milligram-equivalent doses of atorvastatin over simvastatin
Authors: van Dam, M Basart, DCG Janus, C Zwertbroek, R Spierenburg, HAM Werner, HA Bredero, AC Lansberg, PJ Jonker, CJ Trip, MD Prins, MH Kastelein, JJP
Citation: M. Van Dam et al., Additional efficacy of milligram-equivalent doses of atorvastatin over simvastatin, CLIN DRUG I, 19(5), 2000, pp. 327-334
Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer
Authors: Lu, GQ Excoffon, KJDA Wilson, JE McManus, BM Rogers, QR Miao, L Kastelein, JJP Lewis, MES Hayden, MR
Citation: Gq. Lu et al., Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer, HUM GENE TH, 11(1), 2000, pp. 21-32
Screening for familial hypercholesterolaemia - Effective, safe treatments and DNA testing make screening attractive
Authors: Kastelein, JJP
Citation: Jjp. Kastelein, Screening for familial hypercholesterolaemia - Effective, safe treatments and DNA testing make screening attractive, BR MED J, 321(7275), 2000, pp. 1483-1484
Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency
Authors: Hayden, MR Clee, SM Brooks-Wilson, A Genest, J Attie, A Kastelein, JJP
Citation: Mr. Hayden et al., Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency, CURR OP LIP, 11(2), 2000, pp. 117-122
Lipid-altering efficacy and safety of simvastatin 80 mg/day: Worldwide long-term experience in patients with hypercholesterolemia
Authors: Davidson, MH Stein, EA Hunninghake, DB Ose, L Dujovne, CA Insull, W Bertolami, M Weiss, SR Kastelein, JJP Scott, RS Campodonico, S Escobar, ID Schrott, HG Bays, H Stepanavage, ME Wu, M Tate, AC Melino, MR Kush, D Mercuri, M Mitchel, YB
Citation: Mh. Davidson et al., Lipid-altering efficacy and safety of simvastatin 80 mg/day: Worldwide long-term experience in patients with hypercholesterolemia, NUTR MET CA, 10(5), 2000, pp. 253-262
Lipid-altering efficacy and safety of simvastatin 80 mg/day: Long-term experience in a large group of patients with hypercholesterolemia
Authors: Ose, L Davidson, MH Stein, EA Kastelein, JJP Scott, RS Hunninghake, DB Campodonico, S Insull, W Escobar, ID Schrott, HG Stepanavage, ME Wu, M Tate, AC Melino, MR Mercuri, M Mitchel, YB
Citation: L. Ose et al., Lipid-altering efficacy and safety of simvastatin 80 mg/day: Long-term experience in a large group of patients with hypercholesterolemia, CLIN CARD, 23(1), 2000, pp. 39-46
Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis
Authors: Clee, SM Bissada, N Miao, FD Miao, L Marais, AD Henderson, HE Steures, P McManus, J McManus, B LeBoeuf, RC Kastelein, JJP Hayden, MR
Citation: Sm. Clee et al., Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis, J LIPID RES, 41(4), 2000, pp. 521-531
Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes
Authors: Clee, SM Kastelein, JJP van Dam, M Marcil, M Roomp, K Zwarts, KY Collins, JA Roelants, R Tamasawa, N Stulc, T Suda, T Ceska, R Boucher, B Rondeau, C DeSouich, C Brooks-Wilson, A Molhuizen, HOF Frohlich, J Genest, J Hayden, MR
Citation: Sm. Clee et al., Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes, J CLIN INV, 106(10), 2000, pp. 1263-1270
The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia
Authors: Stalenhoef, AFH de Graaf, J Wittekoek, ME Bredie, SJH Demacker, PNM Kastelein, JJP
Citation: Afh. Stalenhoef et al., The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia, ATHEROSCLER, 153(1), 2000, pp. 129-138
Risultati: 1-25 | 26-50 | 51-51